Two infusions of natalizumab (300 mg or 3 mg/kg) vs placebo: Failure to induce clinical response (Panaccione 2010) CDAI ‐ (≥100 point reduction)
Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in failure to induce clinical response at 6 weeks compared with placebo (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Two infusions of natalizumab (300 mg or 3 mg/kg) vs placebo Failure to induce clinical response at 6 weeks · Participants with active Crohn's disease Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in failure to induce clinical response at 6 weeks compared with placebo (low certainty). Natalizumab for induction of remission in Crohn's disease (2018) · Cochrane Headline outcomes only | RR 0.66 [0.35, 1.25] | 2 studies · 1034 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Natalizumab for induction of remission in Crohn's disease 2018 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.